Remibrutinib Enables Peanut Tolerance in as Little as 1 Week, With Robert Wood, MD

Remibrutiib has demonstrated striking early efficacy data in IgE-mediated peanut allergy, with just 1 week of treatment enabling 88% of adult participants to tolerate a previously reactive dose in new phase 2 data presented at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, from February 27 to March 2.

sat down with Robert A. Wood, MD, Chief of the Eudowood Division of Pediatric Allergy and Immunology at Johns Hopkins Children's Center and Professor of Pediatrics at the Johns Hopkins University School of Medicine, who presented the data at the meeting, to learn more about the promising findings and what they may suggest about BTK inhibition’s potential for modifying food allergy. 

The phase 2 study evaluated 3 dose levels of remibrutinib, an oral, highly selective BTK inhibitor, versus placebo in 59 adults with IgE-mediated peanut allergy confirmed by double-blind, placebo-controlled oral food challenge (DBPCFC) at screening. The primary endpoint was tolerating a single dose of ≥600 mg peanut protein without dose-limiting symptoms during DBPCFC at week 4. Four weeks of treatment across the 10, 25, and 100 mg twice-daily dose arms produced estimated response rates (ERR) of 0.41, 0.52, and 0.84, respectively, all superior to placebo. Most striking was the 1-week arm — in which participants received 3 weeks of placebo run-in followed by just 1 week of remibrutinib 25 mg twice daily — which yielded an ERR of 0.88, the highest of any arm in the study. Remibrutinib was well tolerated across all arms with no serious adverse events.

Wood contextualized the mechanism and implications for a field where treatment speed has long been a limiting factor. Remibrutinib works upstream of the allergen-specific pathway, targeting mast cells directly — the final effector cell in IgE-mediated allergic reactions regardless of the triggering allergen. That mechanism carries 2 significant clinical implications: first, the drug is likely to be effective across all food allergens, not just peanut, making it potentially well-suited to the 60–80% of food-allergic patients who react to multiple foods simultaneously. Second, the 1-week onset raises the possibility of intermittent rather than continuous use — providing targeted protection around specific high-risk exposures such as travel or medical procedures, rather than requiring year-round maintenance dosing. 

On the regulatory pathway, Wood noted that remibrutinib is already approved for chronic spontaneous urticaria, clearing an initial safety bar for long-term use, though he flagged that the dose likely required for food allergy efficacy appears higher than the approved urticaria dose, and that dose-dependent safety characterization will be a key focus of the phase 3 trial — which is now underway in adults and adolescents down to age 12, with the question of whether it will extend to younger children dependent on the safety data that emerge from those older cohorts.

“The speed is again, pretty remarkable, and opens the possibility that this treatment might be used intermittently rather than continuously. So if a if a patient with severe food allergy didn't want to be on a long term maintenance medicine, but wanted [short-term] protection… say, for travel,” Wood said.

Wood’s disclosures include Aimmune, ALK, DBV Technologies, FARE, Genentech, NIAID, Novartis, Regeneron, Siolta, and Aravax.

Derman C. FDA Approves Remibrutinib for Chronic Spontaneous Urticaria. HCPLive. Article. September 30, 2025. 

https://www.hcplive.com/view/fda-approves-remibrutinib-chronic-spontaneous-urticaria

Wood R, Tan R, Shah R, et al. Efficacy and safety of remibrutinib, a Bruton’s tyrosine kinase inhibitor, for individuals with IgE-mediated peanut allergy. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #563

Videos

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Hepatitis D: Burden, Testing Gaps, and Emerging Therapies

Despite growing awareness of hepatitis D virus (HDV) infection, experts say the true burden of the disease remains difficult to define, with limited testing, gaps in provider awareness, and historically restricted access to diagnostics all contributing to persistent uncertainty about epidemiology.

, Tatyana Kushner, MD, an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine, noted that routine testing for HDV was not widely recommended until relatively recently, leaving significant blind spots in prevalence estimates. Much of what clinicians know today is based on patients who were tested, diagnosed, and subsequently documented through diagnostic codes or laboratory confirmation. Patients who were never tested, however, remain invisible in these data.

“Up until relatively recently, there was no recommended routine testing for delta hepatitis, and there was somewhat limited access to appropriate testing,” she said. “On top of that, there is still a lack of knowledge about delta hepatitis, so providers don't know who to test, when to test, and about delta hepatitis in general.”

As a result, Kushner noted that prevalence estimates did not include a large portion of patients because they were not being tested or diagnosed. As this has improved over time and experts get a better understanding of HDV epidemiology, geographic gaps in prevalence have become increasingly evident.

Certain regions of the world, including parts of Eastern Europe, Central Asia, and Africa, have a substantially greater prevalence of HDV. In the United States, many patients diagnosed with the infection originate from these endemic regions. However, clinicians are increasingly identifying cases among US-born individuals, raising new questions about transmission patterns and risk factors that are not yet fully understood.

Kushner emphasizes that expanding education and improving access to testing will be critical to refining prevalence estimates. As awareness grows among clinicians and screening becomes more common, researchers may begin to develop a clearer understanding of HDV’s true national and global burden.

At the same time, the treatment landscape for HDV is beginning to evolve after decades of limited therapeutic options. In the absence of US Food and Drug Administration-approved treatments, current guidance from the American Association for the Study of Liver Diseases recommends off-label use of pegylated interferon for patients with active infection who do not have contraindications. However, this therapy presents challenges due to significant side effects and relatively modest efficacy.

“We don't have excellent treatment options available at the moment in the US,” Kushner said. “However, it is a very exciting time, because there are several new treatments on the horizon.”

In Europe, the entry inhibitor bulevirtide is already approved for HDV treatment, supported by both clinical trial and real-world evidence demonstrating meaningful antiviral activity. The therapy requires daily injections, which Kushner says may limit uptake among some patients but has nonetheless represented an important advance.

She pointed to additional therapies that are also progressing through clinical development, specifically highlighting brelovitug, a monoclonal antibody being developed by Mirum Pharmaceuticals that is currently being evaluated in phase 3 trials across multiple countries, including the United States.

“Just 10 years ago, we had nothing available, so I think the field is seeing an exciting development where we hopefully will have options for our patients who really need it,” Kushner said.

Editors’ Note: Kushner reports relevant disclosures with Gilead, Abbvie, GSK, Ipsen, Mirum, and Madrigal.

Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. 

. Published online November 4, 2025. doi:10.1097/HEP.0000000000001549

MYR Pharmaceuticals. MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®. August 4, 2020. Accessed March 12, 2026. 

https://www.prnewswire.com/news-releases/myr-pharmaceuticals-receives-conditional-marketing-authorization-by-the-european-commission-for-hepcludex-301105418.html

Mirum Pharmaceuticals. Mirum Pharmaceuticals Completes AZURE-1 Enrollment and AZURE-4 Screening in Phase 3 Program of brelovitug in Chronic Hepatitis Delta Virus. March 5, 2026. Accessed March 12, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Provides-AZURE-Clinical-Program-Update-for-brelovitug-in-Chronic-Hepatitis-Delta-Virus/default.aspx

Kushner discusses the global burden of hepatitis D, gaps in testing, and emerging therapies reshaping the treatment landscape.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

New Momentum in Hepatitis D Research and Treatment, With Tatyana Kushner, MD

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Remibrutinib Shows Rapid Symptom Relief in CSU, With Mark Lebwohl, MD

Pooled data from the phase 3 REMIX clinical trials

 suggest the oral Bruton’s tyrosine kinase inhibitor remibrutinib may reduce daily disease activity within 12 hours of treatment initiation in patients with 

. Investigators presented the results at the 

2026 American Academy of Allergy, Asthma, & Immunology (AAAAI)

 spoke with investigator Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai, who discussed the clinical implications of these findings and remibrutinib’s impact.

“I vividly recall a woman who was coming to me planning a wedding,” Lebwohl said.

The woman had come covered in urticaria, which had been on her skin for months. With remibrutinib, she could quickly improve her symptoms.

“The ability to give that rapid improvement is such an instant relief, which is greatly appreciated by patients,” he continued. “Often when we start treatments that take a while to work, the patients are not aware [of this fact] ... and they become skeptical that the treatments [are] not working. One of the worst things that happens with some of the other drugs is [that] you're starting a patient on a treatment for chronic urticaria, and they think they can then stop their antihistamines. It turns out, for many of the other treatments, that's a huge problem because the treatments don't kick in sometimes for days or even weeks. With remibrutinib, the treatment kicks in right away.”

The analysis pooled results from the phase 3 REMIX-1 and REMIX-2 trials evaluating remibrutinib 25 mg twice daily in patients with CSU inadequately controlled with H1-antihistamines. Across both studies, 606 and 306 participants received remibrutinib and placebo, respectively. Investigators examined daily disease activity using the daily Urticaria Activity Score (UAS), which ranges from 0 to 6 and incorporates both hive severity and itch intensity.

At baseline, mean daily UAS scores were 4.44 among patients receiving remibrutinib and 4.30 among those receiving placebo. Within 12 hours of the first dose, mean UAS scores declined to 3.96 with remibrutinib compared with 3.99 with placebo. Improvements continued over the first week of treatment; mean scores reached 3.09 vs 3.92 on day 2 and 2.25 vs 3.49 by day 7.

The analysis also examined shifts in symptom severity bands over the first week of treatment. At baseline, only 1.3% of patients receiving remibrutinib and 0.7% of those receiving placebo were classified in the lowest UAS severity band (0–1), representing no or mild symptoms. Within 12 hours, those proportions increased to 6.5% and 2.4%, respectively. By day 7, 37.0% of patients receiving remibrutinib had reached the lowest symptom band compared with 9.7% of patients receiving placebo.

Lebwohl noted that evaluating daily symptom scores rather than relying solely on the traditional weekly UAS7 metric allows clinicians to better understand how quickly therapies begin working. With UAS7, it adds scores over the 7 days; the worst score a patient can get is 21.

“That doesn't really tell us what happens on day 1,” Lebwohl said. “We now have data that in the first 12 hours, patients on remibrutinib have improved.”

Another takeaway from the findings is that remibrutinib appears effective in patients who have previously failed standard therapies. According to Lebwohl, many individuals receiving advanced therapies for CSU have already failed high-dose antihistamines, a prerequisite recommended by current treatment guidelines.

Lebwohl also highlighted the potential impact of remibrutinib’s oral formulation on treatment decisions. While several biologic therapies are available for CSU, they are administered by injection. In contrast, remibrutinib is taken orally, which may influence patient preference.

The study showed adverse events were generally mild. The therapy does not require routine blood monitoring, and the main safety signal noted in clinical trials has been minor bleeding-related events such as petechiae, though Lebwohl has observed this less in practice than as reported in the trials.

Current CSU guidelines recommend omalizumab after failing non-sedating antihistamines. However, after the publication, the FDA had approved dupilumab and remibrutinib for CSU.

“I think all 3 of them, when algorithms or guidelines are developed…will be in the same space where a decision will be made,” Lebwohl said. “All 3 are…good options. Remibrutinib does have the advantage of being fast and being a pill.”

Disclosures for Lebwohl include Boehringer Ingelheim Pharmaceuticals, Incyte Corporation, Genentech USA, Inc., Verrica Pharmaceuticals Inc., PFIZER INC., E.R. Squibb & Sons, L.L.C., Hexal AG, Takeda Pharmaceuticals U.S.A., Inc., MAYNE PHARMA COMMERCIAL LLC, Novartis Pharmaceuticals Corporation, ABBVIE INC., Janssen Biotech, Inc., Amgen Inc., Celltrion, Inc., Almirall LLC, and Incyte Corporation.

Windom H, Machado P, Ortmann CE, et al. Remibrutinib Provides Fast Symptom Relief Within the First Week of Treatment in Chronic Spontaneous Urticaria, as Measured by Daily Urticaria Activity Score: Pooled REMIX-1/-2 Studies. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2025.12.045

At AAAAI 2026, Lebwohl discussed REMIX trial data showing oral remibrutinib reduced CSU symptoms within 12 hours and improved disease control.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Strategic Alliance Partnership

Melissa Wallach, MD, is a pediatrician at K. Hovnanian Children’s Hospital, Hackensack Meridian Jersey Shore University Medical Center.

Meghan Tozzi, MD, is a pediatric cardiologist at Joseph M. Sanzari Children’s Hospital, Hackensack Meridian, Hackensack University Medical Center.

Sugar-Sweetened Beverages in Childhood Increases Diabetes, Hypertension Risk, With Melissa Wallach, MD, and Meghan Tozzi, MD

Despite widespread awareness of the cardiovascular risks of excess sugar intake, it still makes up roughly 17% of a child’s daily calorie intake – half of which is from sugar-sweetened drinks like soda and juice.

Previous research has demonstrated that children who consume >10% of their daily caloric intake from added sugars are more likely to exhibit abnormal cholesterol levels, which is associated with a higher risk of 

Metabolic dysfunction-associated liver disease (MASLD)

 is also a substantial risk factor associated with higher sugar intake.

“We really need to talk to our patients about the fact that, even though the baby in front of you appears very healthy, what we do with regard to their nutrition now can affect long-term things like blood pressure, diabetes, and even fatty liver disease,” Melissa Wallach, MD, a pediatrician at K. Hovnanian Children’s Hospital, Hackensack Meridian Jersey Shore University Medical Center, told 

 in an exclusive interview. “While we have control over what goes in the baby’s mouth, especially at the first year of life, we recommend absolutely no juice.”

Previous scientific statements from the American Heart Association (AHA) recommend that children between 2 and 18 years should have <25 grams of added sugar daily, equating to roughly 6 teaspoons. A substantial amount of this sugar comes from sodas, fruit drinks, sports drinks, and sweet teas – even those marketed as healthy. A single 12-ounce can of soda can contain up to 10 teaspoons of sugar, exceeding the daily recommendation of added sugar and approaching the overall daily sugar limit for children.

Another statement from the AHA functionally defined sugar-sweetened beverages as drinks composed almost exclusively of added sugars and water. The document also provided recommendations to manage children’s access to sugar-sweetened beverages, which include the following:

Avoid soda, sweet tea or coffee, fruit drinks, and sports drinks in favor of serving water or milk

Limit access to fruit juice, which generally has substantially more sugar per serving than whole fruit

Read nutrition labels carefully, as many foods now list added sugar separately. Aim for <25 grams of added sugar per day for children ≥2 years

Limit processed and pre-packaged food and drinks.

A significant degree of exposure to added sugars takes place outside the home, with school lunches often providing juice or chocolate milk to supplement lunches that are already largely empty calories. Additionally, free breakfast and lunch programs, an attempt to provide for lower income families, often presents those children with even higher amounts of added sugar, putting them at greater risk.

“Many of our children, especially from low-income families, do receive the majority of their nutrition at school through free breakfasts and lunches,” Meghan Tozzi, MD, a pediatric cardiologist at Joseph M. Sanzari Children’s Hospital, Hackensack Meridian, Hackensack University Medical Center, told 

. “We’re providing so many empty calories to children – we’re handing them what we’re telling them not to have.”

Editors’ Note: Tozzi and Wallach report no relevant disclosures.

Hackensack Meridian Health. Unmasking the Real Sugar Threat to Our Kids During Heart Month. 

. February 19, 2026. Accessed March 12, 2026. 

https://www.newswise.com/articles/unmasking-the-real-sugar-threat-to-our-kids-during-heart-month

Vos MB, Kaar JL, Welsh JA, et al. Added sugars and cardiovascular disease risk in children: A scientific statement from the American Heart Association. Circulation. 2017;135(19). 

Tozzi and Wallach discuss ways to omit artificial sweeteners and added sugars from children’s diets and minimize risk for T2D and MASLD later in life.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Sugar-Sweetened Beverages in Childhood Increases Diabetes, MASLD Risk, With Melissa Wallach, MD, and Meghan Tozzi, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The landscape of airway disease management has been fundamentally altered by the arrival of biologic therapies targeting type 2 (T2) inflammation. Inhaled corticosteroids, beta-agonists, and anticholinergics once defined the ceiling of what was pharmacologically possible for patients with 

 and COPD — but that ceiling has since shattered. Beginning with omalizumab and continuing through mepolizumab, benralizumab, and dupilumab, a wave of precision agents has reshaped how pulmonologists think about inflammatory airway disease, transforming severe asthma from a condition of symptom management to one where clinical remission is an achievable and increasingly discussed treatment goal.

The pace of that transformation has accelerated in recent years. Dupilumab's 2023 FDA approval for COPD with type 2 inflammation — the first biologic ever cleared for that indication — marked a paradigm shift in how the field approaches a disease long considered beyond the reach of precision medicine.¹ Mepolizumab followed with its own COPD approval, supported by the MATINEE trial, which demonstrated significant exacerbation reduction in patients with blood eosinophil counts of 300 cells/µL or higher.² The GOLD 2025 guidelines have now formally incorporated eosinophil counts and T2 biomarkers into the COPD escalation algorithm,³ and emerging CT-based data on mucus plug scoring are beginning to explain why dupilumab produces such striking improvements in lung function in certain patients.⁴ Meanwhile, tezepelumab — which demonstrated exacerbation reduction regardless of baseline T2 biomarker status in the NAVIGATOR trial⁵ — has challenged the eosinophil-centric framework that guided biologic prescribing for the better part of a decade. Most recently, depemokimab, an ultra-long-acting IL-5 inhibitor dosed every six months, received FDA approval for severe eosinophilic asthma,⁶ introducing a new approach to adherence in difficult-to-treat populations.

It is against this backdrop that HCPLive convened an expert forum on the Evolving Landscape of Targeted Therapy in Asthma and COPD, led by Geoffrey Chupp, MD, Professor of Medicine and director of the Asthma and Airway Disease program at Yale University. The panel included clinicians from academic medical centers and private practice across the Northeast who reviewed the clinical trial evidence base, debated biomarker thresholds, and shared candid accounts of what biologic prescribing actually looks like in busy outpatient clinics — far removed from the controlled environments of phase 3 trials.

The panel reached broad consensus on several core principles while revealing meaningful variation in individual practice. In asthma, blood eosinophils — with a preferred cutoff of ≥300 cells/μL — remain the cornerstone biomarker for biologic initiation, though FeNO and atopy testing add important nuance. Most panelists place patients on a biologic after 2 or more OCS courses per year, though Chupp and others advocated for lower thresholds in highly symptomatic patients even without documented exacerbations. Dupilumab was frequently cited as a first-line choice for patients with nasal polyps or predominant IL-13 signaling, while tezepelumab has emerged as the clear go-to agent for patients with low or absent T2 markers. Depemokimab's 6-month dosing interval generated enthusiasm for vulnerable and non-adherent populations, with panelists generally favoring a short-acting IL-5 first to confirm efficacy before transitioning. The long-term extension data for all approved biologics showed consistent durability, and newer trial data on mucus plug scores — from the VESTIGE trial with dupilumab and the CASCADE trial with tezepelumab — added a compelling radiographic dimension to understanding how these drugs drive lung function improvements.

“It's helpful to have a marker to trend in these patients to sort of see did the biologic really improve things or not. I think I have a pretty similar threshold to others and what others have mentioned in terms of actually starting a biologic. I mean, typically one course of prednisone won't do it for me. But if they're one course and they're really uncontrolled, multiple courses, like two courses, I'm definitely starting,” Sandy Zaeh, MD, MS, Pulmonary & Critical Care Medicine physician at Yale School of Medicine, said during the forum.

In COPD, the panel reflected a field still finding its footing with biologic therapy. Dupilumab was the dominant choice in practice, backed by the stronger exacerbation and lung function data from BOREAS and NOTUS, while mepolizumab's COPD uptake remained limited, hampered by comparatively modest effect sizes in MATINEE and insurance access barriers that panelists in New Jersey and other markets described vividly. Several clinicians noted that COPD patients are meaningfully harder to engage with biologic therapy than asthma patients — older, more injection-averse, and often skeptical that additional treatment can improve their quality of life. Yet those who have initiated therapy described consistently positive patient experiences, with even modest functional gains translating into meaningful improvements in daily life. The group identified long-term lung function trajectory data, clearer patient selection algorithms, and improved payer alignment as the most pressing unmet needs — and one panelist made the case bluntly: if a single avoided COPD hospitalization can offset years of biologic costs, the math on coverage restrictions is hard to defend.

Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. 

. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951

Eger K, Hashimoto S, Braunstahl GJ, et al. Mepolizumab for eosinophilic COPD with exacerbations (MATINEE). 

. 2024;391(1):21-31. doi:10.1056/NEJMoa2401300

Global Initiative for Chronic Obstructive Lung Disease. 

Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report

Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. 

. 2018;128(3):997-1009. doi:10.1172/JCI95693

Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. 

. 2021;384(19):1800-1809. doi:10.1056/NEJMoa2034975

Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the efficacy and safety of depemokimab in patients with severe asthma with an eosinophilic phenotype (SWIFT-1 and SWIFT-2). 

. 2024;404(10471):2373-2385. doi:10.1016/S0140-6736(24)02063-4

Articles

Type 2–targeted biologics have expanded airway disease management beyond inhaled therapies, reframing severe asthma around achievable clinical remission and introducing precision medicine into selected COPD. Recent milestones include dupilumab and mepolizumab approvals for eosinophilic COPD and guideline integration of eosinophils/T2 biomarkers into escalation pathways, alongside emerging CT mucus-plug phenotyping. Expert consensus favors eosinophils ≥300/µL plus FeNO/atopy to refine asthma selection, with practice variation around OCS thresholds, agent choice, and real-world adherence challenges.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Eosinophils, Exacerbations, and Endpoints: Biologic Therapy Selection in COPD and Asthma

Experts discuss the clinical significance of the updated international CSU guidelines, which for the first time incorporate 3 step-up therapy options.

Overview of the New International CSU Guidelines and Expanded Treatment 

Nicole Negbenebor, MD, is a clinical assistant professor of dermatology and the director of the Skin of Color Clinic for the University of Iowa, as well as a Skin of Color Society (SOCS) member.

In this segment of the latest Skin of Color Savvy podcast, Nicole Negbenebor, MD, highlights her experiences as director of a Skin of Color Clinic.

Discussing Work as the Director of a Skin of Color Clinic in Dermatology

Experts discuss the goal of complete symptom control in CSU and the practical limitations of achieving complete control of disease.

Treatment Goals, Disease Control Targets, and the Role of Patient-Reported Outcome Measures 

Matthew Krantz, MD, from Vanderbilt University Medical Center

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

HCPLive Five at AAAAI 2026

Lala discusses the ethical, medical, and practical concerns surrounding xenotransplantation of pig hearts – and how they should be addressed in clinical research.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ISHLT Provides Updates in Xenografting in Patients with Cardiac Diseases, With Anu Lala, MD

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Is Expedited Kidney Donation More Effective Than In-Sequence?

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Wood discussed factors that go into shared decision making for multi-food allergy.

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

Daniel DiGiacomo, MD, a clinical immunologist at K. Hovnanian Children's Hospital at Hackensack Meridian Jersey Shore University Medical Center. 

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.


Latest News

Remibrutinib Enables Peanut Tolerance in as Little as 1 Week, With Robert Wood, MD

New Momentum in Hepatitis D Research and Treatment, With Tatyana Kushner, MD

Remibrutinib Shows Rapid Symptom Relief in CSU, With Mark Lebwohl, MD

Sugar-Sweetened Beverages in Childhood Increases Diabetes, MASLD Risk, With Melissa Wallach, MD, and Meghan Tozzi, MD

Eosinophils, Exacerbations, and Endpoints: Biologic Therapy Selection in COPD and Asthma